Giovanni Addolorato, Antonio Mirijello, Pablo Barrio, Antoni Gual 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 53, Issue 1, Pages (July 2010)
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Volume 67, Issue 3, Pages (September 2017)
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
Volume 68, Issue 5, Pages (May 2018)
Primary prevention of variceal haemorrhage: A pharmacological approach
Volume 61, Issue 6, Pages (December 2014)
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Volume 51, Issue 6, Pages (December 2009)
The impact of hepatitis E in the liver transplant setting
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis
Volume 66, Issue 1, Pages 1-4 (January 2017)
Volume 69, Issue 1, Pages (July 2018)
Lorenzo Leggio, MD, PhD, MSc, Mary R. Lee, MD 
Living donor liver transplantation: is the hype over?
Mesenchymal stromal cell therapy for liver diseases
Volume 69, Issue 2, Pages (August 2018)
Volume 44, Pages S19-S24 (January 2006)
The place of downstaging for hepatocellular carcinoma
Volume 58, Issue 3, Pages (March 2013)
Why is the surgical high-risk patient still at risk?
Autoimmune hepatitis: A life-long disease
Jordan J. Feld, Graham R. Foster  Journal of Hepatology 
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
European Association for the Study of the Liver  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Volume 70, Issue 1, Pages (January 2019)
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Volume 54, Issue 5, Pages (May 2011)
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
Genomic risk of hepatitis C-related hepatocellular carcinoma
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
The changing role of beta-blocker therapy in patients with cirrhosis
S. Tamir Rashid, Graeme J.M. Alexander  Journal of Hepatology 
Volume 57, Issue 5, Pages (November 2012)
Volume 50, Issue 4, Pages (April 2009)
Non-invasive diagnosis and biomarkers in alcohol-related liver disease
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Volume 67, Issue 3, Pages (September 2017)
Immigration and viral hepatitis
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Volume 63, Issue 1, Pages (July 2015)
Familial amyloidosis: Great progress for an orphan disease
The use of hemospray in portal hypertensive bleeding; a case series
Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice  Paolo Angeli, Pere Gines 
New trials and results in systemic treatment of HCC
Liver transplantation in children
Reply to: “Flow cytometry makes all the difference”
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Genetics of hepatocellular carcinoma: The next generation
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Treatment of alcohol use disorders in patients with alcoholic liver disease  Giovanni Addolorato, Antonio Mirijello, Pablo Barrio, Antoni Gual  Journal of Hepatology  Volume 65, Issue 3, Pages 618-630 (September 2016) DOI: 10.1016/j.jhep.2016.04.029 Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Environment (including alcohol availability) associated to genetic predisposition to alcohol addiction and to neuro-psychological impairment (i.e. mood and affective disorders and/or craving onset) increase the risk of Alcohol Use Disorders (AUD) development. AUD is the most frequent cause of liver diseases in the Western world. The most effective management strategy for AUD patients with liver diseases is to achieve total alcohol abstinence. The combination of psychosocial interventions and pharmacological therapy represent the most effective treatment to achieve abstinence and to prevent relapse. Alcohol abstinence leads to an improvement of liver function and/or to a reduction of liver disease progression. Journal of Hepatology 2016 65, 618-630DOI: (10.1016/j.jhep.2016.04.029) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions